1415609-40-3Relevant academic research and scientific papers
Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond
G?ring, Stefan,Taymans, Jean-Marc,Baekelandt, Veerle,Schmidt, Boris
, p. 4630 - 4637 (2014)
The most prevalent leucine-rich repeat kinase 2 (LRRK2) mutation G2019S is associated with Parkinson's disease (PD). It enhances kinase activity and has been identified in both familial and sporadic cases. Kinase activity was reported to be required for LRRK2 mutants to exert their toxic effects. Hence LRRK2 kinase inhibition may be a promising therapeutic target for PD. Here we report on the discovery and characterization of indolinone based LRRK2 inhibitors. Indolinone 15b, the most potent and selective inhibitor of the present series, is characterized by an IC50of 15 nM against wild-type LRRK2 and 10 nM against the LRRK2 G2019S mutant, respectively. Compound 15b was further evaluated in a kinase panel including 46 human protein kinases and in a zebrafish embryo phenotype assay, which enabled toxicity determination in whole organisms.
Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3
Amombo, Ghislaine Marlyse Okala,Kramer, Thomas,Lo Monte, Fabio,Goering, Stefan,Fach, Matthias,Smith, Steven,Kolb, Stephanie,Schubenel, Robert,Baumann, Karlheinz,Schmidt, Boris
, p. 7634 - 7640 (2013/02/21)
The inhibition of FLT-3 activity is an interesting target for the treatment of acute myeloid leukemia (AML). The serendipitous identification of FLT-3 inhibitors from a CK1/γ-secretase programme provided compounds with dual inhibitory activity. We analyzed the structure-activity relationship of these inhibitors and derivatized them to arrive at compounds with reduced impact on γ-secretase activity and enhanced FLT-3 inhibition.
